Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Contract Assets and Liabilities (Details)

v3.23.1
Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 1,121 $ 1,898
Long-term pharma contract assets 0 31
Total pharma contract assets 1,121 1,929
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 912 800
Long-term pharma capitalized commissions 632 715
Total pharma capitalized commissions 1,544 1,515
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 6,067 7,557
Long-term pharma contract liabilities 0 19
Total pharma contract liabilities $ 6,067 $ 7,576